VANRAFIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANRAFIA (VANRAFIA).
Vanrafia acts as a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
| Metabolism | Vanrafia undergoes minimal metabolism via glucuronidation by UGT1A9 and UGT2B7; primarily excreted unchanged in urine. |
| Excretion | Primarily via feces (80–90%) as unchanged drug and metabolites; renal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is 120–216 hours (5–9 days) in healthy volunteers; prolonged in hepatic impairment. |
| Protein binding | 99% bound primarily to serum albumin. |
| Volume of Distribution | Vd is approximately 0.11–0.20 L/kg, reflecting distribution mainly in plasma and interstitial fluid. |
| Bioavailability | Oral: 95–100% with minimal first-pass metabolism; interindividual variability due to CYP2C9 and VKORC1 polymorphisms. |
| Onset of Action | Oral: 2–5 days to achieve therapeutic INR; IV: 12–24 hours for initial suppression of vitamin K-dependent factors. |
| Duration of Action | Anticoagulant effect persists for 48–96 hours after single dose; recovery of clotting factors may take 7–10 days upon cessation. |
| Molecular Weight | 370.4 |
10 mg orally three times daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | GFR 30-49 mL/min: 10 mg twice daily; GFR <30 mL/min: 10 mg once daily; Hemodialysis: 10 mg once daily after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 10 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | 1-2 mg/kg/day divided every 8 hours, maximum 30 mg/day. |
| Geriatric use | No specific adjustment; caution in age >75 years due to increased fall risk; monitor renal function. |
| 1st trimester | Contraindicated due to teratogenicity (central nervous system and cardiovascular malformations) |
| 2nd trimester | Contraindicated due to fetal hemorrhage and placental abruption risk |
| 3rd trimester | Contraindicated due to premature closure of ductus arteriosus and oligohydramnios |
Clinical note
Comprehensive clinical and safety monograph for VANRAFIA (VANRAFIA).
| Placental transfer | Extensive placental transfer; achieves fetal plasma concentrations 50-100% of maternal levels. |
| Breastfeeding | Excreted in breast milk; not recommended due to potential adverse effects in nursing infant (e.g., renal impairment, bleeding). |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to vanrafia or any excipientActive gastrointestinal bleedingBleeding disorders (e.g., hemophilia, thrombocytopenia)Severe hepatic impairment (Child-Pugh C)Severe renal impairment (eGFR < 30 mL/min)Concurrent use of anticoagulants or antiplatelet agentsHistory of intracranial hemorrhagePregnancy (all trimesters)Lactation
| Precautions | Risk of diabetic ketoacidosis (DKA), including atypical presentations with euglycemia, Acute kidney injury, especially in volume-depleted patients, Increased risk of lower limb amputations (observed in clinical trials), Necrotizing fasciitis of the perineum (Fournier gangrene), Genital mycotic infections, particularly in uncircumcised males, Hypotension and volume depletion, Elevated LDL cholesterol |
| Food/Dietary | Avoid alcohol and grapefruit juice as they may increase side effects or reduce efficacy. High-fat meals may affect absorption; take consistently relative to meals. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | Vanrafia (roflumilast) is contraindicated in pregnancy. First trimester: Associated with increased risk of congenital malformations, particularly cardiac and skeletal defects, based on animal studies. Second and third trimesters: Risk of fetal toxicity and low birth weight. Use only if maternal benefit outweighs fetal risk, with informed consent. |
| Fetal Monitoring | Monitor maternal liver function tests (ALT, AST) monthly; perform renal function tests; assess for psychiatric symptoms (anxiety, depression, suicidality). Fetal monitoring with ultrasound for growth restriction and anomalies if exposure occurs; consider fetal echocardiography. |
| Fertility Effects | In animal studies, roflumilast did not significantly impair fertility; however, due to anti-inflammatory effects, theoretical risk of altered gonadal function. Human data limited; advise patients of potential for reversible effects on spermatogenesis or ovulation. |
| Clinical Pearls | Vanrafia is a brand name for rifaximin, a non-absorbable antibiotic. Monitor for C. difficile colitis; use with caution in severe hepatic impairment. Avoid concurrent use with P-glycoprotein inhibitors like cyclosporine. |
| Patient Advice | Take this medication with or without food exactly as prescribed. · Do not take with alcohol or alcoholic beverages. · Report any signs of liver problems (yellowing skin/eyes, dark urine) or severe diarrhea. · Complete the full course even if you feel better. · Inform your doctor of all medications you take, especially other antibiotics or P-glycoprotein inhibitors. |